Jaguar Health, Inc. (NASDAQ:JAGX)

BRIEF

published on 04/01/2024 at 14:05, 7 months 22 days ago

Jaguar Health Reports Financial Downturn in 2023 Results

Financial Results Revenue Decline Jaguar Health Mytesi Phase 3 Trial
PRESS RELEASE

published on 04/01/2024 at 14:00, 7 months 22 days ago

Jaguar Health Reports 2023 Financial Results
Jaguar Health, Inc. reports an 18% decrease in net revenue for 2023 compared to 2022. Phase 3 OnTarget trial details and upcoming investor webcast disclosed

Financial Results Investor Webcast Jaguar Health Inc. Net Revenue Phase 3 OnTarget Trial
BRIEF

published on 03/27/2024 at 13:35, 7 months 28 days ago

Jaguar Health, Inc. Schedules Investor Webcast for Q4 2023 Financial Review and Updates

Pharmaceuticals Investor Webcast Jaguar Health Financials Corporate Update
PRESS RELEASE

published on 03/27/2024 at 13:30, 7 months 28 days ago

Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
Jaguar Health, Inc. (NASDAQ:JAGX) will conduct an investor webcast on April 1, 2024, at 8:30 a.m. EST to review fourth-quarter financials and corporate updates. Company plans to file its Earnings Report on Form 10-K for year ended December 31, 2023

Earnings Report Investor Webcast Jaguar Health Financials Form 10-K
BRIEF

published on 03/20/2024 at 13:35, 8 months 4 days ago

Jaguar Health, Inc. Secures Licensing Agreement with GEN for Crofelemer in Nine Countries

Crofelemer Jaguar Health Mytesi GEN Pharmaceutical Licensing
PRESS RELEASE

published on 03/20/2024 at 13:30, 8 months 4 days ago

GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
Jaguar Health, Inc. announces exclusive license agreement with GEN for crofelemer products in key territories, including payment of double-digit royalties. Agreement covers FDA-approved indications and potential follow-on uses

FDA-approved GEN Crofelemer Products Double-digit Royalties License Agreement
PRESS RELEASE

published on 02/23/2024 at 14:30, 9 months ago

Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
Jaguar Health Provides Update on Nasdaq Listing Status. Company requests appeal hearing after receiving delisting notification. Working on comprehensive analysis of Phase 3 trial for cancer therapy-related diarrhea prevention

Crofelemer Nasdaq Listing Jaguar Health Cancer Therapy Phase 3 Trial
BRIEF

published on 02/23/2024 at 14:30, 9 months ago

Jaguar Health, Inc.: Update on Its Nasdaq Listing Status

Crofelemer Nasdaq Jaguar Health Clinical Trial Gastrointestinal Treatment
PRESS RELEASE

published on 02/15/2024 at 14:30, 9 months 8 days ago

Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Animal Health announces agreement with FDA on clinical field study design for Canalevia-CA1, a canine-specific treatment for chemotherapy-induced diarrhea in dogs, towards full approval

Canalevia-CA1 Chemotherapy-induced Diarrhea Jaguar Animal Health FDA Agreement Clinical Field Study
PRESS RELEASE

published on 02/14/2024 at 14:30, 9 months 9 days ago

Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
Jaguar Health, Inc. donates plant-based drug Mytesi® to Direct Relief, aiding healthcare access. Mytesi® helps HIV/AIDS patients with noninfectious diarrhea. Learn more at https://jaguar.health

Healthcare Access Jaguar Health Inc. Mytesi Direct Relief Plant-based Drug

Published on 11/22/2024 at 23:55, 1 day 13 hours ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 14 hours ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 14 hours ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 1 day 14 hours ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 15 hours ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 1 day 19 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 1 day 19 hours ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 1 day 19 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 20 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 1 day 21 hours ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 1 day 23 hours ago

Thales Press release
Published on 11/21/2024 at 06:58, 3 days 6 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 3 days 18 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 3 days 19 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 3 days 19 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News